MedPath

Hyperthyroidism: Methimazole Plus L-carnitine and Selenium

Not Applicable
Conditions
Hyperthyroidism
Interventions
Dietary Supplement: L-carnitine+Selenium
Registration Number
NCT04946123
Lead Sponsor
Lo.Li.Pharma s.r.l
Brief Summary

The study aims to investigate the benefits of methimazole treatment in patients with hyperthyroidism, associated with supplementation of L-carnitine and Selenium.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
60
Inclusion Criteria
  • Diagnosis of hyperthyroidism requiring therapy with methimazole
Exclusion Criteria
  • Drug and alcohol abuse;
  • Pregnancy;
  • Medically uncontrolled psychiatric conditions;
  • Interfering therapies (lithium, interferone, TKI, amiodarone)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
methimazole+L-carnitine+selenium (intervention)L-carnitine+SeleniumPatients with hyperthyroidism under methimazole treatment + supplementation with L-carnitine and Selenium
Primary Outcome Measures
NameTimeMethod
Hyperthyroidism symptomsChange from 6-months supplementation QoL at 12 months of intervention (end of study)

Improvement of the patients' quality of life through questionnaire

Secondary Outcome Measures
NameTimeMethod
TRAbFour time points: baseline; after 3 months of supplementation; after 6 months of supplementation; end of the study (12 months)

Change in serum TRAb (TSH receptor antibodies)

TSHFour time points: baseline; after 3 months of supplementation; after 6 months of supplementation; end of the study (12 months)

Change in serum TSH (Thyroid stimulating hormone)

Trial Locations

Locations (1)

Azienda Ospedaliero-Universitaria Città della scienza e degli studi di Torino

🇮🇹

Torino, Italy

© Copyright 2025. All Rights Reserved by MedPath